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costs, we assumed that a treatment was provided to every patient who visited the 
dentist according to the national dental cavities guideline, all related costs were 
obtained from the SOAT fare manual 2011 reported by the government. We multiplied 
the treatment cost for each patient by the total number of dental visits to obtain the 
third-payer cost. We calculated from the patient´s perspective the lost output as a 
result of a reduction of productivity due to dental cavities, using DALYs, multiplied by 
the 2011 current GDP divided by the working-age population. RESULTS: The Economic 
impact for 2011 was USD 67.018.016. This is the result of adding the third-payer cost of 
USD 56.234.161 plus the patient cost of USD 10.783.855. CONCLUSIONS: With this first 
approximation to the economic impact of dental cavities the government can design 
cost-effective oral health policies to reduce its prevalence for Colombia’s population. 
The cost of dental cavities represents 0.02% of 2011 current GDP, this means that on 
average there is an expenditure of USD 1.46 for each Colombian citizen to treat dental 
cavities. Those numbers shows the importance to generate permanent public policies 
to improve the Colombians´ oral health.
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OBJECTIVES: Psoriasis (PSO) is an immune-mediated systemic inflammatory dis-
ease. The therapeutic classes available to treat PSO include biologic drugs. Despite 
rising wholesale acquisition costs of biologics in recent years, little documented 
evidence is available on cost trends from the US managed care perspective. This 
analysis determines the change in healthcare costs for PSO patients to managed care 
organizations. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient 
diagnoses for PSO (ICD-9: 696.1) were selected from the MarketScan Commercial and 
Medicare Supplemental databases if their first biologic prescription date (index date) 
occurred July 2008 through July 2013 and they were biologic naive ≥ 6 months pre-
index. Healthcare costs were based on annual reimbursements for 6 patient cohorts 
initiating biologic therapy from 2008 to 2013. Results were stratified by all-cause vs. 
PSO-related costs and further subdivided into medical inpatient, medical outpatient, 
emergency room, and pharmacy costs. RESULTS: 13,045 patients met the inclusion 
criteria and composed the 6 cohorts. All-cause annual healthcare costs for the years 
2008-2013 were $27,973, $31,507, $35,006, $38,533, $42,289, and $43,431, showing 
increases of 55.3% overall and averaging 11.1% or $3,092 annually. Respective PSO-
related estimated annual costs were $19,991, $21,976, $25,059, $27,853, $31,575, and 
$32,739, showing increases of 63.8% overall and averaging 12.8% or $2,550 annually. 
Although costs increased over time in all categories assessed, the major driver of 
this trend was PSO-related pharmacy costs, predominantly the cost of biologic thera-
pies. These costs were estimated for the years 2008-2013 at $15,871, $18,032, $21,403, 
$22,880, $27,899, and $29,240, showing increases of 84.2% overall and averaging 16.8% 
or $2,674 annually. CONCLUSIONS: For US managed care payers, total healthcare cost 
incurred for patients initiated on biologic therapy for PSO has increased substantially 
in recent years, primarily driven by changes in PSO-related pharmacy costs.
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OBJECTIVES: Injection frequency and costs were examined for aflibercept 2.0 mg and 
ranibizumab 0.5 mg intravitreal injections in patients with neovascular age-related 
macular degeneration (AMD) or central retinal vein occlusion (RVO), and for ranibi-
zumab 0.3 mg injections in patients with diabetic macular edema (DME). METHODS: 
This retrospective US claims study analyzed patients who started first-line treatment 
with ranibizumab or aflibercept (index date [ID]) between 11/18/2011-1/31/2014 for 
AMD, 9/21/2013-7/31/2014 for RVO, and 8/10/2012-1/31/2014 for DME, and met the fol-
lowing criteria: aged ≥ 18y on ID; no bilateral disease; ≥ 12 months continuous coverage 
before ID (baseline period); AMD, RVO or DME diagnosis (ICD-9-CM 362.52, 362.35, or 
362.07) during baseline period or on ID; and 12 months of post-ID follow-up coverage 
without switching therapies. Twelve-month outcomes were number of injections and 
their respective costs. Injection frequency and costs were compared for aflibercept 
vs ranibizumab in multivariate regression models that adjusted for possible con-
founding variables (reference= ranibizumab, all comparisons). RESULTS: In AMD and 
RVO analyses, aflibercept (AMD:N= 316, RVO:N= 55) and ranibizumab (AMD:N= 875; 
RVO:N= 154) recipients had similar unadjusted mean number of injections (AMD:5.6 
vs 5.3, respectively; RVO:4.5 vs 5.0, respectively) and related costs (AMD:$11,372 vs 
$10,856, respectively; RVO:$8219 vs $9733, respectively) at 12 months. In AMD regres-
sion analyses, number and costs of injections were not significantly different between 
aflibercept and ranibizumab (Incidence Rate Ratio [IRR]= 1.05, 95% confidence interval 
[CI]= 0.98-1.13, P= 0.17; Cost Ratio [CR]= 1.04, 95%CI= 0.96-1.14, P= 0.34). Similar results 
were seen for RVO (IRR= 0.91, 95%CI= 0.76-1.10, P= 0.35; CR= 0.89, 95%CI= 0.72-1.11, 
P= 0.31). In DME patients (N= 92), at 12 months, the mean (SD) number of ranibizumab 
0.3 mg injections was 4.4 (2.9) and mean costs were $5289 ($3524). CONCLUSIONS: In 
AMD and RVO patients, injection frequency and costs for aflibercept and ranibizumab 
treatments were similar at 12 months. Mean annual costs of treating DME patients 
with ranibizumab were lower than for AMD and RVO patients.
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to provide an insight regarding interrelationship between the psychological stress as 
one of the contributing factor towards acne among final year pharmacy students at 
International Islamic University Malaysia. METHODS: This cross sectional study was 
conducted by distributing questionnaire among 98 final year students. Information 
on severity of acne and level of stress was collected by using the Global Acne Severity 
Scale (GEA) and the Perceived Stress Scale (PSS) which is a psychological test for 
assessing stress. RESULTS: The results obtained shows that there is positive correla-
tion between acne vulgaris and stress, however it is not significant. The severity of 
the acne such as the open and close comedones, into papules, pustules, and nodules 
and even cysts are also related with several factors which may exacerbate the acne 
conditions. Among those factors are gender and family history, exposure to sunlight, 
diet, lifestyle such as sleep and exercise, skin condition, and also intervention in solv-
ing acne problem. CONCLUSIONS: In conclusion, there is a positive relation between 
acne vulgaris and stress. The acne condition exacerbates in more stressful conditions.
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OBJECTIVES: Incidence and burden data for severe Chronic Hand Eczema (sCHE) 
is limited. In the absence of other means of gathering this data, the study’s pri-
mary objective was to generate estimates for global 1-year period prevalence for 
sCHE. Secondary objectives included an estimate of sufferers whose condition is 
inadequately managed with topical steroids. METHODS: An online survey, aiming 
for nationally representative samples, to 34,765 respondents in USA, UK, France, 
Germany, Japan, India, Brazil, China, recruited via consumer panels. Respondents were 
classified sufferers of sCHE via questions on length of time experiencing symptoms, 
frequency and duration of flares, affected hand surface area, and on severity, using 
the photographic scale developed by Coenraads et al (2005). 147 sufferers meeting 
the qualifying criteria for sCHE completed questions on diagnosis, treatment and 
disease burden. RESULTS: We present our results in the form of descriptive statistics. 
An estimated global1-year period prevalence for sCHE of 0.54% was found, after data 
adjustment to reflect the population of 18-75 year olds by geographical region, and 
projection to total population. This is consistent with the range reported by Diepgen 
et al. (2007) (0.5%-0.7%). Of those classified as sCHE sufferers, 53% reported having 
received a medical diagnosis of sCHE; of these 80.2% had received treatment during 
the study period. 47% of those treated were classified as potentially refractory to topi-
cal steroids. The impact of the disease on the total sufferer population was greatest in 
social activities. CONCLUSIONS: Our results indicate a lower than expected diagnosis 
level of sCHE, given its prevalence and impact on sufferers. We also found that topical 
steroid treatment is unlikely to adequately control symptoms in significant numbers 
of cases of sCHE. We believe our methodology is an innovative alternative, consistent 
with a scientific approach, allowing sizing and understanding of sufferer populations, 
particularly in under-diagnosed conditions.
PSS9
the PReValence of age-Related maculaR degeneRation in indian 
PoPulation: a SyStematic ReView
Likhar N., Mothe R.K., Kanukula R., Shah C., Dang A.
MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
OBJECTIVES: Age-related macular degeneration (AMD) is the leading cause of visual 
impairment and blindness in India. A clear understanding of the AMD burden in 
India is essential to meet future demands for eye health care. The current analysis 
aims to evaluate the prevalence of AMD in India through a systematic review of pub-
lished peer-reviewed studies. METHODS: Observational studies reporting the preva-
lence of AMD patients in India were retrieved from an electronic literature search 
in PubMed, Cochrane and EMBASE using the terms age-related macular degenera-
tion, prevalence, and India. Search limits applied included articles in English, in 
human adults, and published since the year 2004. Two researchers independently 
extracted the data along with critical appraisal of the studies. Descriptive statistics 
was performed for comparable outcomes. RESULTS: A total of seven studies met the 
inclusion criteria. The overall prevalence of AMD in India ranges from 1.4% to 3.1%. 
The prevalence was lowest in West India (1.4%) and highest in South India (3.1%). 
We found a higher prevalence of early AMD than late AMD (2.3% vs. 0.6%). AMD was 
more prevalent in rural areas than in urban (2.3% vs.2.1%) and in females than males 
(2.5% vs. 1.9%). The most important demographic factor affecting the prevalence of 
AMD in India appears to be the age (> 65 years). CONCLUSIONS: The prevalence of 
AMD in India has been increasing over the years. It is an emerging challenge for eye 
care and public health professionals in India. Further studies in Indian population 
are warranted to investigate the epidemiological patterns of specific AMD subtypes.
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OBJECTIVES: According to the burden disease calculated by Ramirez et. al. (2005), in 
Colombia dental cavities represented the third disease with most DALYs for both gen-
ders in all age groups. Also, the Ministry of Health and Social Protection (2012) reported 
that dental cavities were a leading cause of morbidity in 2011 with 1.360.619 occur-
rences in the health system. Because of this, we decided to determine the economic 
cost of dental cavities in Colombia from the third-payer and patient perspectives for 
year 2011. METHODS: We used the official SISPRO data to get information regarding 
the number of visits per patient who had dental cavities. To calculate the monetary 
